Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Daiichi Sankyo
Age
40–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed diagnosis of heterozygous familial hypercholesterolemia
Ambulatory male (40 to 75 years, inclusive) or female (45 to 75 years, inclusive) subjects
Calculated LDL-C level greater than or equal to 100 mg/dL (or 2.5 mmol/L) and triglycerides less than 500 mg/dL (5.65 mmol/L) while on usual and stable lipid-lowering therapy
You may not be if
Breast feeding or lactating women
Previous organ transplantation
High-grade stenosis (\>75%) or the occlusion of any segment of either carotid artery
History of carotid endarterectomy, or insertion of carotid artery stent or are scheduled to have either of these procedures
Clareo Health | Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.
